机构:[1]Laboratory of Human Diseases and Immunotherapies, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[3]Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[4]Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院
This work was financially supported by grants from the National Natural Science Foundation of China (21977076). We sincerely appreciate the HEK293-SOCS3-Luc cells, a gift from GenEros BioPharma Ltd. We thank Qifeng Liu and Feijing Su (Core Facilities of West China Hospital) for NMR recording, as well as Qianlun Pu (Mass Spectrometry Center of West China Hospital) for HRMS recording.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
无
最新[2023]版:
大类|2 区医学
小类|1 区药物化学
第一作者:
第一作者机构:[1]Laboratory of Human Diseases and Immunotherapies, West China Hospital, Sichuan University, Chengdu, 610041, China[2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China[3]Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China
共同第一作者:
通讯作者:
通讯机构:[1]Laboratory of Human Diseases and Immunotherapies, West China Hospital, Sichuan University, Chengdu, 610041, China[2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China[3]Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China[*1]State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center for Biotherapy, and Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, 610041, China.[*2]State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.[*3]Laboratory of Human Diseases and Immunotherapies, West China Hospital, Sichuan University, Chengdu, 610041, China.
推荐引用方式(GB/T 7714):
Zhang Lidan,Liu Pingxian,Jiang Yunhan,et al.Exploration of novel isoxazole-fused quinone derivatives as anti-colorectal cancer agents through inhibiting STAT3 and elevating ROS level[J].European Journal Of Medicinal Chemistry.2024,272:116448.doi:10.1016/j.ejmech.2024.116448.
APA:
Zhang Lidan,Liu Pingxian,Jiang Yunhan,Fan Dongmei,He Xinlian...&Yang Tao.(2024).Exploration of novel isoxazole-fused quinone derivatives as anti-colorectal cancer agents through inhibiting STAT3 and elevating ROS level.European Journal Of Medicinal Chemistry,272,
MLA:
Zhang Lidan,et al."Exploration of novel isoxazole-fused quinone derivatives as anti-colorectal cancer agents through inhibiting STAT3 and elevating ROS level".European Journal Of Medicinal Chemistry 272.(2024):116448